New product for primary prevention of VTE

Boehringer Ingelheim has announced the launch of a new oral anticoagulant dabigatran etexliate (Pradaxa) for the primary prevention of venous thromboembolic events (VTE) in adults who have undergone elective total hip or total knee replacement surgery. Click here for more details